Cases
Cerevel Therapeutics Holdings, Inc. Investigation
- Corporate Governance / Derivative Action
Overview
Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: Cerevel Therapeutics Holdings, Inc. |
| Stock Symbol: | Stock Symbol: CERE |
Bleichmar Fonti & Auld LLP is currently investigating the potential merger between Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE), and AbbVie Inc. for $45 per share to determine whether Cerevel’s board of directors: (1) agreed to an unfair amount to be paid to shareholders; (2) subject to conflicts of interest; and/or (3) engaged in an unfair process.
If you still own shares of Cerevel, you are encouraged to fill out the form below to get more information and speak with an attorney about your rights.
Investigation Details:
BFA is investigating whether the $45 per share offer for Cerevel is unfair to shareholders. On December 6, 2023, Cerevel announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to close in the middle of 2024. Cerevel’s stock is currently trading just above $42.
BFA Law is currently investigating this transaction and believes that Cerevel’s board of directors is conflicted, engaged in an unfair process, and agreed to an unfair amount to be paid to shareholders. Based on the public announcement, we believe the offer is unfair to investors and the price should be higher.
Next Steps:
If you currently own shares of Cerevel you may have legal options and you are encouraged to submit your information to speak with an attorney.
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Contact:
Ross Shikowitz
ross@bfalaw.com
212-789-2303
Fill out the form below for more information.
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder derivative litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
If you still own shares of Cerevel, you are encouraged to fill out the form below to get more information and speak with an attorney about your rights.
Investigation Details:
BFA is investigating whether the $45 per share offer for Cerevel is unfair to shareholders. On December 6, 2023, Cerevel announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to close in the middle of 2024. Cerevel’s stock is currently trading just above $42.
BFA Law is currently investigating this transaction and believes that Cerevel’s board of directors is conflicted, engaged in an unfair process, and agreed to an unfair amount to be paid to shareholders. Based on the public announcement, we believe the offer is unfair to investors and the price should be higher.
Next Steps:
If you currently own shares of Cerevel you may have legal options and you are encouraged to submit your information to speak with an attorney.
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Contact:
Ross Shikowitz
ross@bfalaw.com
212-789-2303
Fill out the form below for more information.
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder derivative litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
For Further Information Please Fill Out the Form Below